We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc., for the commercialization of bentracimab in 49 countries across Europe and other key markets.
PhaseBio Pharmaceuticals, a clinical-stage biotech focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra, a global contract development and manufacturing organization (CDMO), have entered a ...